The developers of a new South San Francisco biotech campus are blueprinting plans for a boutique hotel to complete the R&D community, according to The Daily Journal. The developers say it will act as something of a community center for the 21-acre development, which will add a 400,000 R&D tower near the 400,000 square foot structure already on the property. South San Francisco has been seeing a variety of new biotech campuses take shape over the past year as the industry booms and big outfits like Merck and AstraZeneca scout new California hubs.
AstraZeneca has completed its deal to out-license the IL-23 antibody MEDI-2070 to Allergan. The drug is currently in a Phase IIb for Crohn’s disease.
The scandal surrounding Valeant’s ties to Philidor keeps growing. The Wall Street Journal reports that federal prosecutors plan to charge a Valeant exec and ex-Philidor CEO Andrew Davenport on charges of engaging in fraud and a major kickback scheme.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription